CP
OTLK icon

Caligan Partners’s Outlook Therapeutics OTLK Stock Holding History

Caligan Partners’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-318,699
Closed -$1.7M – 16
2024
Q3 		$1.7M Sell
318,699
-181,301
-36% -$1.33M 0.54% 12
2024
Q2 		$3.69M Hold
500,000
– – 0.86% 13
2024
Q1 		$5.97M Buy
+500,000
New +$4.04M 1.58% 10

Other funds holding OTLK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Caligan Partners's OTLK Position: Q4 2024 in Review

Caligan Partners sold out of Outlook Therapeutics (OTLK) in Q4 2024, closing a stake of 318,699 shares — an estimated $1.7M sold.

Caligan Partners first reported a position in OTLK in Q1 2024 and held it in 3 quarters. The position peaked at $5.97M in Q1 2024. 61 funds tracked by Wall St. Rank hold OTLK as of Q4 2024.

  • Caligan Partners reported no remaining Outlook Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Caligan Partners sold 318,699 Outlook Therapeutics shares in Q4 2024, an estimated $1.7M.
  • Caligan Partners first reported a position in Outlook Therapeutics in Q1 2024 and held it in 3 quarters.
  • Caligan Partners's Outlook Therapeutics position peaked at $5.97M in Q1 2024.
  • 61 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q4 2024.

Based on Caligan Partners's 13F filing for Q4 2024, filed 14 Feb 2025.